Dr. Davis has received consultancies and/or honoraria (less than $10,000 each) from Amgen, Centocor, and Abbott. Dr. Revicki has received consultancies and/or honoraria (less than $10,000) from Abbott. Dr. van der Heijde has received consultancies and/or honoraria (less than $10,000 each) from Abbott, Amgen, Centocor, Wyeth, UCB, Merck, and Schering-Plough. Drs. Kupper, Luo, and Wong own stock in Abbott.
Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study
Article first published online: 30 JUL 2007
Copyright © 2007 by the American College of Rheumatology
Arthritis Care & Research
Volume 57, Issue 6, pages 1050–1057, 15 August 2007
How to Cite
Davis, J. C., Revicki, D., van der Heijde, D. M. F., Rentz, A. M., Wong, R. L., Kupper, H. and Luo, M. P. (2007), Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study. Arthritis & Rheumatism, 57: 1050–1057. doi: 10.1002/art.22887
- Issue published online: 30 JUL 2007
- Article first published online: 30 JUL 2007
- Manuscript Accepted: 14 DEC 2006
- Manuscript Received: 10 AUG 2006
- Abbott Laboratories
- United BioSource Corporation
- 1Epidemiology of ankylosing spondylitis. In: HochbergMC, SilmanAJ, SmolenJS, WeinblattME, WeismanMH, editors. Rheumatology. 3rd ed. Volume 2. Edinburgh: Mosby; 2003. p. 1153–9., .
- 10Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis on concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400–11., , , , , , et al.
- 11Adalimumab, a fully human anti–tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30: 2563–71., , , , , , et al.
- 13Adalimumab Effectiveness in Psoriatic Arthritis Trial Study. Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279–89., , , , , , et al, for the
- 16Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582–91., , , , , , et al, for the
- 29SF-36 Health Survey: manual and interpretation guide. Lincoln (RI): Quality Metric Inc.; 2000., , .
- 30SF-36 physical and mental health summary scores: a user's manual. Boston: The Health Institute, New England Medical Center; 1994., , .
- 37Design and analysis of quality of life studies in clinical trials. Boca Raton: Chapman & Hall/CRC; 2002..